The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.
Roger Stupp
Consultant or Advisory Role - Merck Serono; Merck Sharp & Dohme; Roche/Genentech
Honoraria - Merck Serono; Merck Sharp & Dohme; Roche/Genentech
Monika E. Hegi
Consultant or Advisory Role - MDxHealth; MSD
Honoraria - MDxHealth; MSD
Research Funding - MDxHealth
Thierry Gorlia
No relevant relationships to disclose
Sara Erridge
No relevant relationships to disclose
Danica Grujicic
No relevant relationships to disclose
Joachim Peter Steinbach
Consultant or Advisory Role - Roche
Research Funding - Merck KGaA
Wolfgang Wick
Consultant or Advisory Role - Magforce; MSD; Roche
Honoraria - MSD; Roche
Research Funding - Boehringer Ingelheim; Lilly; MSD; Roche
Rafal Tarnawski
No relevant relationships to disclose
Do-Hyun Nam
No relevant relationships to disclose
Astrid Weyerbrock
No relevant relationships to disclose
Peter Hau
No relevant relationships to disclose
Martin JB Taphoorn
Consultant or Advisory Role - Roche
Honoraria - Roche
Louis B. Nabors
No relevant relationships to disclose
David A. Reardon
Consultant or Advisory Role - Amgen; EMD Serono; Merck; Novartis; Roche/Genentech
Honoraria - EMD Serono; Merck; Roche/Genentech
Martin J. Van Den Bent
Consultant or Advisory Role - Merck Serono; MSD; Roche; Siena Biotech
Honoraria - MSD
Research Funding - Roche
James R. Perry
Honoraria - Merck
Yong Kil Hong
No relevant relationships to disclose
Christine Hicking
Employment or Leadership Position - Merck KGaA
Stock Ownership - Merck KGaA
Martin Picard
Employment or Leadership Position - Merck KGaA
Michael Weller
Consultant or Advisory Role - Antisense Pharma; Merck Serono; Roche
Honoraria - Merck Serono; MSD; Roche
Research Funding - Antisense Pharma; Merck Serono; MSD; Roche